{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:30:25Z","timestamp":1787671825634,"version":"build-2736575974"},"reference-count":42,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with myelodysplastic syndrome (MDS)\/acute myeloid leukemia (AML) with high-risk features including TP53 mutations have poor outcomes because of the lack of effective therapies. The atypical chemokine surface receptor C-C motif chemokine receptor-like 2 (CCRL2) is overexpressed in MDS and secondary AML compared with healthy hematopoietic cells, and we recently found that TP53-mutated MDS\/AML and AML with erythroid features express the highest levels of this receptor across MDS\/AML subtypes. To illustrate the therapeutic potential of CCRL2 as a therapeutic target, we developed an anti-CCRL2 antibody-drug conjugate (ADC) by conjugating an anti-CCRL2 antibody with the cytotoxic drug pyrrolobenzodiazepine (PBD), which causes DNA double-strand breaks, leading to cancer cell death. Anti-CCRL2 ADC demonstrated strong CCRL2-selective cytotoxicity associated with DNA damage against cell lines derived from patients with MDS\/AML with TP53 mutations and erythroid features, surpassing the cytotoxic effects observed with gemtuzumab and PBD-conjugated anti-CD33 and anti-CD123 ADCs. It also induced apoptosis and suppressed the clonogenicity of primary MDS\/AML bone marrow samples without affecting the survival, differentiation, and clonogenicity of healthy hematopoietic stem and progenitor cells. This agent also suppressed the leukemic growth of TP53-mutated MDS\/AML cell line xenografts, improving mice survival and decreasing the leukemic burden in patient-derived TP53-mutated MDS\/AML xenografts. In conclusion, our study introduces CCRL2 as a potential new therapeutic target in high-risk MDS\/AML, including TP53-mutated subsets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019380","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:54:46Z","timestamp":1779310486000},"page":"5653-5668","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["A PBD dimer\u2013containing antibody-drug conjugate targeting CCRL2 for high-risk MDS\/AML including\n                    <i>TP53<\/i>\n                    -mutated disease"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4761-7435","authenticated-orcid":false,"given":"Nour Sabiha","family":"Naji","sequence":"first","affiliation":[{"name":"1Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medical Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Ahmedna","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medical Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD"},{"name":"2Ludwig Center and Lustgarten Laboratory, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghan","family":"Zeng","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medical Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuju","family":"An","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medical Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashvi","family":"Hemani","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medical Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandy","family":"Perkins","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medical Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zanshe","family":"Thompson","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar D.","family":"Nichakawade","sequence":"additional","affiliation":[{"name":"2Ludwig Center and Lustgarten Laboratory, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1903-182X","authenticated-orcid":false,"given":"Yanyan","family":"Wang","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medical Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bum Seok","family":"Lee","sequence":"additional","affiliation":[{"name":"2Ludwig Center and Lustgarten Laboratory, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline","family":"Watson","sequence":"additional","affiliation":[{"name":"2Ludwig Center and Lustgarten Laboratory, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6931-5828","authenticated-orcid":false,"given":"Theodora","family":"Chatzilygeroudi","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medical Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8680-4119","authenticated-orcid":false,"given":"Li","family":"Luo","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Paun","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medical Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Klausner","sequence":"additional","affiliation":[{"name":"4Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Supeanu","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medical Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0312-3412","authenticated-orcid":false,"given":"Ivana","family":"Gojo","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medical Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3955-7944","authenticated-orcid":false,"given":"Gabriel","family":"Ghiaur","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medical Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"DeZern","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medical Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0473-6982","authenticated-orcid":false,"given":"Mark J.","family":"Levis","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medical Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Resar","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medical Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6314-6881","authenticated-orcid":false,"given":"J. David","family":"Peske","sequence":"additional","affiliation":[{"name":"5Division of Hematopathology, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2387-6075","authenticated-orcid":false,"given":"Styliani","family":"Karanika","sequence":"additional","affiliation":[{"name":"6Division of Infectious Diseases, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9357-3702","authenticated-orcid":false,"given":"Suman","family":"Paul","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medical Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD"},{"name":"2Ludwig Center and Lustgarten Laboratory, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Karantanos","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medical Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"issue":"2","key":"2026082510523979900_bib1","first-page":"339","article-title":"Treatment of high-risk myelodysplastic syndromes","volume":"110","author":"Kr\u00f6ger","year":"2025","journal-title":"Haematologica"},{"issue":"11","key":"2026082510523979900_bib2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","article-title":"TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions","volume":"12","author":"Daver","year":"2022","journal-title":"Cancer Discov"},{"issue":"9","key":"2026082510523979900_bib3","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/s41375-023-01985-y","article-title":"Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification","volume":"37","author":"Hochman","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2026082510523979900_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2026082510523979900_bib5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"2026082510523979900_bib6","doi-asserted-by":"crossref","first-page":"1533796","DOI":"10.3389\/fimmu.2025.1533796","article-title":"Six events that shaped antibody approvals in oncology","volume":"16","author":"Paul","year":"2025","journal-title":"Front Immunol"},{"issue":"4","key":"2026082510523979900_bib7","first-page":"303","article-title":"The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma","volume":"140","author":"Calabretta","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2026082510523979900_bib8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"20","key":"2026082510523979900_bib9","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.3390\/cancers16203489","article-title":"Antibody-based therapies for peripheral T-cell lymphoma","volume":"16","author":"Shafagati","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"20","key":"2026082510523979900_bib10","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.2023020630","article-title":"Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial","volume":"142","author":"Freeman","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2026082510523979900_bib11","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2026082510523979900_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41408-023-00910-x","article-title":"Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia","volume":"13","author":"Awada","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026082510523979900_bib13","doi-asserted-by":"crossref","first-page":"615031","DOI":"10.3389\/fcell.2020.615031","article-title":"Molecular basis for CCRL2 regulation of leukocyte migration","volume":"8","author":"Schioppa","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"2026082510523979900_bib14","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/2326-6066.CIR-19-0168","article-title":"The atypical receptor CCRL2 is essential for lung cancer immune surveillance","volume":"7","author":"Del Prete","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"2026082510523979900_bib15","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1182\/blood-2017-04-777680","article-title":"The atypical receptor CCRL2 is required for CXCR2-dependent neutrophil recruitment and tissue damage","volume":"130","author":"Del Prete","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2026082510523979900_bib16","doi-asserted-by":"crossref","first-page":"eabl8952","DOI":"10.1126\/sciadv.abl8952","article-title":"The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia","volume":"8","author":"Karantanos","year":"2022","journal-title":"Sci Adv"},{"issue":"7","key":"2026082510523979900_bib17","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3324\/haematol.2022.281444","article-title":"CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine","volume":"108","author":"Karantanos","year":"2023","journal-title":"Haematologica"},{"issue":"2","key":"2026082510523979900_bib18","first-page":"493","article-title":"C-C motif chemokine receptor-like 2 promotes the interferon-\u03b3 signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53","volume":"111","author":"Naji","year":"2026","journal-title":"Haematologica"},{"issue":"9","key":"2026082510523979900_bib19","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41588-023-01480-1","article-title":"Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution","volume":"55","author":"Rodriguez-Meira","year":"2023","journal-title":"Nat Genet"},{"issue":"1","key":"2026082510523979900_bib20","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/s41467-024-45916-6","article-title":"Comprehensive characterization of IFN\u03b3 signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"issue":"5","key":"2026082510523979900_bib21","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/leu.2013.372","article-title":"An MDS xenograft model utilizing a patient-derived cell line","volume":"28","author":"Rhyasen","year":"2014","journal-title":"Leukemia"},{"issue":"8007","key":"2026082510523979900_bib22","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41586-024-07233-2","article-title":"TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers","volume":"628","author":"Nichakawade","year":"2024","journal-title":"Nature"},{"issue":"12","key":"2026082510523979900_bib23","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/s43018-025-01069-z","article-title":"TRBC2-targeting antibody-drug conjugates for the treatment of T cell cancers","volume":"6","author":"Ge","year":"2025","journal-title":"Nat Cancer"},{"key":"2026082510523979900_bib24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-1-4939-2422-6_12","article-title":"Visualizing TCR-induced POLKADOTS formation and NF-\u03baB activation in the D10 T-cell clone and mouse primary effector T cells","volume":"1280","author":"Paul","year":"2015","journal-title":"Methods Mol Biol"},{"key":"2026082510523979900_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-1-4939-6881-7_8","article-title":"T cell receptor activation of NF-\u03baB in effector T cells: visualizing signaling events within and beyond the cytoplasmic domain of the immunological synapse","volume":"1584","author":"Traver","year":"2017","journal-title":"Methods Mol Biol"},{"issue":"325","key":"2026082510523979900_bib26","doi-asserted-by":"crossref","first-page":"ra45","DOI":"10.1126\/scisignal.2004882","article-title":"T cell receptor signals to NF-\u03baB are transmitted by a cytosolic p62-Bcl10-Malt1-IKK signalosome","volume":"7","author":"Paul","year":"2014","journal-title":"Sci Signal"},{"issue":"1","key":"2026082510523979900_bib27","doi-asserted-by":"crossref","first-page":"10479","DOI":"10.1038\/s41598-018-28533-4","article-title":"Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine","volume":"8","author":"Hartley","year":"2018","journal-title":"Sci Rep"},{"issue":"10","key":"2026082510523979900_bib28","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood"},{"issue":"19","key":"2026082510523979900_bib29","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"issue":"20","key":"2026082510523979900_bib30","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026082510523979900_bib31","doi-asserted-by":"crossref","first-page":"106860","DOI":"10.1016\/j.leukres.2022.106860","article-title":"Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy","volume":"118","author":"Tashakori","year":"2022","journal-title":"Leuk Res"},{"issue":"5","key":"2026082510523979900_bib32","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/leu.2016.309","article-title":"Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia","volume":"31","author":"Khan","year":"2017","journal-title":"Leukemia"},{"issue":"17","key":"2026082510523979900_bib33","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2016-01-689976","article-title":"The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia","volume":"127","author":"Olombel","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2026082510523979900_bib34","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1158\/1078-0432.CCR-20-2399","article-title":"Inotuzumab ozogamicin for relapsed\/refractory acute lymphoblastic leukemia in the INO-VATE trial: CD22 pharmacodynamics, efficacy, and safety by baseline CD22","volume":"27","author":"Kantarjian","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2026082510523979900_bib35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood-2017-06-789800","article-title":"A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2026082510523979900_bib36","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","article-title":"SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML","volume":"122","author":"Kung Sutherland","year":"2013","journal-title":"Blood"},{"issue":"9825","key":"2026082510523979900_bib37","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"issue":"suppl 15","key":"2026082510523979900_bib38","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/JCO.2020.38.15_suppl.7508","article-title":"Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML)","volume":"38","author":"Ravandi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026082510523979900_bib39","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2023-179667","article-title":"CD33 CAR T-cells (CD33CART) for children and young adults with relapsed\/refractory AML: dose-escalation results from a phase I\/II multicenter trial","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"key":"2026082510523979900_bib40","doi-asserted-by":"crossref","first-page":"1501329","DOI":"10.3389\/fimmu.2025.1501329","article-title":"Targeting CCRL2 enhances therapeutic outcomes in a tuberculosis mouse model","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"issue":"11","key":"2026082510523979900_bib41","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","article-title":"ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies","volume":"15","author":"Flynn","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"2026082510523979900_bib42","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/16\/5653\/2538023\/blooda_adv-2025-019380-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/16\/5653\/2538023\/blooda_adv-2025-019380-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:59:06Z","timestamp":1787669946000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/16\/5653\/568543\/A-PBD-dimer-containing-antibody-drug-conjugate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":42,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019380","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,25]]},"published":{"date-parts":[[2026,8,14]]}}}